Executives of Inspire Pharmaceuticals recently met again with the Food and Drug Administration to discuss the dry-eye drug the FDA has so far rejected.
No further action was reported other than Inspire said it would offer more information to the FDA in the future. The most recent discussion took place on March 22.
“Based upon this meeting, we intend to provide the FDA with additional information to facilitate ongoing discussions related to diquafosol,” said Christy Shaffer, president and chief executive officer of Inspire, in a statement.” We have discussed these plans with our partner, Allergan, Inc., and appreciate Allergan’s support throughout this process. We expect to provide the information to the FDA and continue our discussions with them over the next several months.”